|Bid||9.30 x 200|
|Ask||16.50 x 100|
|Day's Range||10.24 - 10.86|
|52 Week Range||5.42 - 25.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
-Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders-. -Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer-.
NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...
-Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study–. -Data Help Clarify Protocol Design for Planned ...
NEW YORK, NY / ACCESSWIRE / September 29, 2017 / Zynerba scored a big win yesterday after announcing positive results from its trial of ZYN002, a cannabidiol gel that is aimed to reduce symptoms of fragile ...
NEW YORK, NY / ACCESSWIRE / August 14, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Disappointing quarterly results combined with rising geopolitical tensions Wednesday to pressure U.S. markets lower on Wednesday. On Wednesday, North Korean ...
NEW YORK, NY / ACCESSWIRE / July 11, 2017 / A rally by technology stocks helped lift U.S. markets Monday. While the S&P 500 Index's Technology sector has fallen approximately 3 percent from its high set ...